A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Trial ID or NCT#

NCT01677390

Status

not recruiting iconNOT RECRUITING

Purpose

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Official Title

A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression - Previously treated with at least 1 tyrosine kinase inhibitor (TKI) - Measurable disease - Eastern Cooperative Oncology Group performance status 0 or 1 - Adequate lung and renal function
Exclusion Criteria:
  1. - Prior treatment with anti-CD70-directed therapy - Received more than one prior treatment with an mTOR inhibitor
View All Criteria
Show Less

Investigator(s)

Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov